Filing Details
- Accession Number:
- 0001209191-18-011324
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-02-20 16:21:56
- Reporting Period:
- 2018-02-15
- Accepted Time:
- 2018-02-20 16:21:56
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1503802 | Karyopharm Therapeutics Inc. | KPTI | Pharmaceutical Preparations (2834) | 263931704 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1603510 | Brett Christopher Primiano | C/O Karyopharm Therapeutics Inc. 85 Wells Avenue Newton MA 02459 | Evp, Cbo, Gc & Secretary | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2018-02-15 | 1,014 | $15.02 | 8,867 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-02-16 | 1,486 | $15.01 | 7,381 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.04, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each price.
- Represents the weighted average sale price. These shares were sold in transactions at $15.00 and $15.08. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each price.
Billionaire Hedge Funds
